Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, HC Wainwright Analyst Says

Eton Pharmaceuticals (NASDAQ:ETON) had its price target increased by equities research analysts at HC Wainwright from $37.00 to $52.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 132.97% from the stock’s previous close.

Several other equities analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. B. Riley Financial upped their price target on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. Zacks Research raised shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Craig Hallum lifted their price objective on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $39.33.

Eton Pharmaceuticals Stock Up 7.5%

ETON opened at $22.32 on Friday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.25 and a current ratio of 1.63. The company has a market cap of $598.62 million, a price-to-earnings ratio of -123.99 and a beta of 1.19. Eton Pharmaceuticals has a one year low of $11.09 and a one year high of $23.00. The business’s fifty day moving average is $16.72 and its two-hundred day moving average is $17.38.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings results on Thursday, March 19th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). The firm had revenue of $21.28 million during the quarter, compared to analysts’ expectations of $20.58 million. Eton Pharmaceuticals had a negative net margin of 5.75% and a negative return on equity of 2.66%. Analysts anticipate that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue purchased a new position in Eton Pharmaceuticals in the 3rd quarter valued at about $30,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Eton Pharmaceuticals during the second quarter worth about $37,000. Quarry LP acquired a new position in shares of Eton Pharmaceuticals in the third quarter valued at approximately $37,000. Legal & General Group Plc acquired a new position in shares of Eton Pharmaceuticals in the second quarter valued at approximately $41,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at approximately $44,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Key Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Several brokerages raised price targets and reiterated buy ratings (HC Wainwright to $52, B. Riley to $31, Craig Hallum to $35), increasing upside expectations and driving bullish investor sentiment. Analyst Upgrades
• Positive Sentiment: Eton acquired U.S. rights to HEMANGEOL, expanding its commercial portfolio in a specialty/rare-disease area and creating a clearer near-term revenue pathway. Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
• Positive Sentiment: Market commentary highlights a meaningful consensus upside — Zacks notes analysts’ mean targets imply roughly a 49% rally — reinforcing the bullish narrative from upgraded targets. Does Eton Pharmaceuticals Have the Potential to Rally 49.25%?
• Neutral Sentiment: Earnings call and company commentary emphasized record revenue growth and commercial progress, which supports the growth story but did not fully offset margin pressures. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Reported short-interest data for March appears anomalous/flat (0 shares reported and a 0.0 days-to-cover), so it’s unlikely to be a material driver of today’s move. (Data looks unreliable.)
• Negative Sentiment: Q4 results: revenue beat slightly ($21.28M vs. $20.58M est.) but EPS missed ($0.05 vs. $0.12 est.); the company still reports negative net margin and negative ROE, raising profitability concerns. Eton Pharmaceuticals Reports Q4 & Full-Year 2025 Results
• Negative Sentiment: Analyst coverage also flagged the EPS miss in headlines (Zacks: earnings lag estimates), which could cap near-term sentiment until margins improve. Eton Q4 Earnings Lag Estimates

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.